Tag: argenx
December 19, 2018
Biotech Outlook 2019: Will the Pressure Continue?
With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
October 3, 2018
VIDEO — Life Science Update September 2018
With September officially behind us, the Investing News Network is taking a look back at some of the biggest news...
September 17, 2018
Argenx Releases Positive Trial Results
On Monday, Argenx released positive clinical data from a proof-of-concept trial for its rare disease drug, efgartigimoid (ARGX-113). September 17, 2018
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
argenx (Nasdaq:ARGX) announced positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod (ARGX-113) in adult primary immune... June 6, 2018
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment... May 9, 2018
argenx reports first quarter 2018 financial results and provides business update
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment... March 22, 2018